Inovio announces positive preliminary results from second cohort of phase 1/2 trial with ino-3107 for the treatment of recurrent respiratory papillomatosis

10 of 11 patients (91%) had a reduction in number of surgical interventions, measured from day 0 to one year following initial treatment; 4 of the 10 patients did not need any surgery treatment with ino-3107 achieved statistical significance based on clinical endpoint of reduction in overall number of surgical interventions compared with previous year ino-3107 was well-tolerated and immunogenic, with efficacy and safety results for second cohort consistent with first cohort patients in second cohort were administered ino-3107 using the exploratory side port needle plymouth meeting, pa. , feb. 16, 2023 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-associated diseases, cancer, and infectious diseases, today announced positive preliminary results from the second cohort of its phase 1/2 clinical trial evaluating ino-3107 for the treatment of hpv 6 and hpv 11-associated recurrent respiratory papillomatosis (rrp) in adults.
INO Ratings Summary
INO Quant Ranking